Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The stock is trading with a P/E ratio of 7.98, which compares to its industry's average of 15.63. Over the last 12 months, PFE's Forward P/E has been as high as 12.11 and as low as 7.15, with a ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Pfizer Inc. (NYSE:PFE) is one of the Best Large Cap Value Stocks to Invest In. Morningstar reduced its moat rating for the ...

Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. Although Pfizer has made some efforts to turn things around, they have been insufficient.

One stock to keep an eye on is Pfizer ... so they are often considered a better performance indicator. PFE has a P/S ratio of 2.1. This compares to its industry's average P/S of 3.16. ...